Breast Cancer Update - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

Breast Cancer Update — Health & Fitness
Breast Cancer Update

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Copyright: © Copyright 2009 Research To Practice. All Rights Reserved

Latest Episodes:

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders Nov 05, 2025

Show notes

Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.

CME information and select publications here.

Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Oct 27, 2025

Show notes

Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates Oct 21, 2025

Show notes

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment Oct 14, 2025

Show notes

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer.

CME information and select publications here.

Breast Cancer — An ASCO 2025 Review Oct 07, 2025

Show notes

Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting.

CME information and select publications here.

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Sep 29, 2025

Show notes

Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management Sep 23, 2025

Show notes

Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer.

CME information and select publications here.

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy Sep 18, 2025

Show notes

Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.

CME information and select publications here.

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management Sep 16, 2025

Show notes

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.

CME information and select publications here.

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management Sep 15, 2025

Show notes

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies.

CME information and select publications here.

Related Podcasts